![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to launch SunWay's inaugural product, MenaQ7® Metabolic, featuring two key active ingredients, MenaQ7® Vitamin K2 as MK-7 and ANKASCIN® 568-R.
Lead Product(s): Menaquinone-7,Ankascin 568-R
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MenaQ7
Highest Development Status: Phase IVProduct Type: Small molecule
Recipient: SunWay Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 14, 2024
Details:
This acquisition brings together globally recognized vitamin K2 brands vitaMK7® and MenaQ7® and allows Gnosis by Lesaffre to offer to the market the most complete portfolio of solutions, adapted to each market need and able to satisfy all customers.
Lead Product(s): Vitamin K2
Therapeutic Area: Musculoskeletal Product Name: MenaQ7
Highest Development Status: Phase IVProduct Type: Small molecule
Recipient: NattoPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 25, 2021